{
  "success": true,
  "fetched_at": "2026-01-11T02:37:54.635664",
  "ticker": "4528",
  "ticker_full": "4528.T",
  "company_name": "ONO PHARMACEUTICAL CO",
  "company_info": {
    "name_en": "ONO PHARMACEUTICAL CO",
    "long_name": "Ono Pharmaceutical Co., Ltd.",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "website": "https://www.ono-pharma.com",
    "employees": 4287,
    "country": "Japan",
    "city": "Osaka",
    "address": "8-2, Kyutaromachi 1-chome",
    "description": "Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and Sibylla Biotech for central nervous system disorders. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan."
  },
  "price_trend": {
    "ma_5": {
      "ma_value": 2222.6,
      "deviation": 2.25,
      "trend": "up"
    },
    "ma_25": {
      "ma_value": 2182.7,
      "deviation": 4.11,
      "trend": "up"
    },
    "ma_75": {
      "ma_value": 1976.67,
      "deviation": 14.97,
      "trend": "up"
    },
    "ma_200": {
      "ma_value": 1732.96,
      "deviation": 31.13,
      "trend": "up"
    }
  },
  "financials": {
    "years": [
      {
        "year": 2025,
        "revenue": 486871000000.0,
        "revenue_fmt": "¥4869億",
        "gross_profit": 338921000000.0,
        "gross_profit_fmt": "¥3389億",
        "operating_income": 59748000000.0,
        "operating_income_fmt": "¥597億",
        "ebit": 64646000000.0,
        "ebit_fmt": "¥646億",
        "net_income": 50047000000.0,
        "net_income_fmt": "¥500億",
        "eps": 106.41,
        "operating_margin": 12.27,
        "total_assets": 1064046000000.0,
        "total_assets_fmt": "¥1.1T",
        "total_equity": 782451000000.0,
        "total_equity_fmt": "¥7825億",
        "total_debt": 146678000000.0,
        "total_debt_fmt": "¥1467億",
        "total_cash": 204567000000.0,
        "total_cash_fmt": "¥2046億",
        "equity_ratio": 73.54,
        "de_ratio": 0.19,
        "current_ratio": 3.07,
        "operating_cf": 82459000000.0,
        "operating_cf_fmt": "¥825億",
        "investing_cf": -136785000000.0,
        "investing_cf_fmt": "-¥1368億",
        "financing_cf": 94299000000.0,
        "financing_cf_fmt": "¥943億",
        "free_cf": 74469000000.0,
        "free_cf_fmt": "¥745億",
        "net_margin": 10.28,
        "roe": 6.4,
        "roa": 4.7
      },
      {
        "year": 2024,
        "revenue": 502672000000.0,
        "revenue_fmt": "¥5027億",
        "gross_profit": 375547000000.0,
        "gross_profit_fmt": "¥3755億",
        "operating_income": 159936000000.0,
        "operating_income_fmt": "¥1599億",
        "ebit": 163963000000.0,
        "ebit_fmt": "¥1640億",
        "net_income": 127977000000.0,
        "net_income_fmt": "¥1280億",
        "eps": 266.57,
        "operating_margin": 31.82,
        "total_assets": 913668000000.0,
        "total_assets_fmt": "¥9137億",
        "total_equity": 792961000000.0,
        "total_equity_fmt": "¥7930億",
        "total_debt": 8862000000.0,
        "total_debt_fmt": "¥89億",
        "total_cash": 166141000000.0,
        "total_cash_fmt": "¥1661億",
        "equity_ratio": 86.79,
        "de_ratio": 0.01,
        "current_ratio": 3.99,
        "operating_cf": 110660000000.0,
        "operating_cf_fmt": "¥1107億",
        "investing_cf": 48077000000.0,
        "investing_cf_fmt": "¥481億",
        "financing_cf": -89848000000.0,
        "financing_cf_fmt": "-¥898億",
        "free_cf": 89831000000.0,
        "free_cf_fmt": "¥898億",
        "net_margin": 25.46,
        "roe": 16.14,
        "roa": 14.01
      },
      {
        "year": 2023,
        "revenue": 447187000000.0,
        "revenue_fmt": "¥4472億",
        "gross_profit": 337124000000.0,
        "gross_profit_fmt": "¥3371億",
        "operating_income": 141963000000.0,
        "operating_income_fmt": "¥1420億",
        "ebit": 144445000000.0,
        "ebit_fmt": "¥1444億",
        "net_income": 112723000000.0,
        "net_income_fmt": "¥1127億",
        "eps": 230.79,
        "operating_margin": 31.75,
        "total_assets": 882437000000.0,
        "total_assets_fmt": "¥8824億",
        "total_equity": 741869000000.0,
        "total_equity_fmt": "¥7419億",
        "total_debt": 9168000000.0,
        "total_debt_fmt": "¥92億",
        "total_cash": 96135000000.0,
        "total_cash_fmt": "¥961億",
        "equity_ratio": 84.07,
        "de_ratio": 0.01,
        "current_ratio": 2.81,
        "operating_cf": 159610000000.0,
        "operating_cf_fmt": "¥1596億",
        "investing_cf": -100259000000.0,
        "investing_cf_fmt": "-¥1003億",
        "financing_cf": -32484000000.0,
        "financing_cf_fmt": "-¥325億",
        "free_cf": 145113000000.0,
        "free_cf_fmt": "¥1451億",
        "net_margin": 25.21,
        "roe": 15.19,
        "roa": 12.77
      },
      {
        "year": 2022,
        "revenue": 361361000000.0,
        "revenue_fmt": "¥3614億",
        "gross_profit": 267850000000.0,
        "gross_profit_fmt": "¥2678億",
        "operating_income": 103196000000.0,
        "operating_income_fmt": "¥1032億",
        "ebit": 105899000000.0,
        "ebit_fmt": "¥1059億",
        "net_income": 80519000000.0,
        "net_income_fmt": "¥805億",
        "eps": 162.16,
        "operating_margin": 28.56,
        "total_assets": 739203000000.0,
        "total_assets_fmt": "¥7392億",
        "total_equity": 655906000000.0,
        "total_equity_fmt": "¥6559億",
        "total_debt": 8802000000.0,
        "total_debt_fmt": "¥88億",
        "total_cash": 69112000000.0,
        "total_cash_fmt": "¥691億",
        "equity_ratio": 88.73,
        "de_ratio": 0.01,
        "current_ratio": 4.27,
        "operating_cf": 61829000000.0,
        "operating_cf_fmt": "¥618億",
        "investing_cf": 6038000000.0,
        "investing_cf_fmt": "¥60億",
        "financing_cf": -60237000000.0,
        "financing_cf_fmt": "-¥602億",
        "free_cf": 49552000000.0,
        "free_cf_fmt": "¥496億",
        "net_margin": 22.28,
        "roe": 12.28,
        "roa": 10.89
      }
    ],
    "has_data": true
  },
  "dividends": {
    "history": [
      {
        "year": 2021,
        "amount": 50.5
      },
      {
        "year": 2022,
        "amount": 61.0
      },
      {
        "year": 2023,
        "amount": 77.0
      },
      {
        "year": 2024,
        "amount": 80.0
      },
      {
        "year": 2025,
        "amount": 80.0
      }
    ],
    "latest": 40.0,
    "has_data": true
  }
}